ACAD ACADIA Pharmaceuticals Inc.

22.93
+0.67  (+3%)
Previous Close 22.26
Open 22.44
Price To Book 12.81
Market Cap 2867959592
Shares 125,074,557
Volume 1,404,949
Short Ratio
Av. Daily Volume 1,708,285

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released October 31, 2018 - noted overall primary endpoint met BUT did not benefit placebo in re-randomized stage.
Pimavanserin - CLARITY
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 initiated November 2016. Enrolment to be completed 2H 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016. Data due mid-2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 3 interim data 2H 2019.
Pimavanserin - Harmony
Alzheimer’s disease psychosis

Latest News

  1. ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
  2. What's in the Cards for Bausch Health (BHC) Q4 Earnings?
  3. 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
  4. New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  5. ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
  6. Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
  7. Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
  8. Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
  9. See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
  10. Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
  11. Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
  12. Is a Beat in Store for Vertex (VRTX) This Earnings Season?
  13. MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
  14. Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals
  15. Will ACADIA Pharmaceuticals Continue to Surge Higher?
  16. Does ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) CEO Pay Compare Well With Peers?
  17. Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
  18. Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD)